Product Data Sheet

Methylnitronitrosoguanidine

Cat. No.: HY-128612 CAS No.: 70-25-7 Molecular Formula: C,H,N,O, Molecular Weight: 147.09

DNA Alkylator/Crosslinker Target: Pathway: Cell Cycle/DNA Damage Storage:

Pure form -20°C 3 years 4°C 2 years

SOLVENT & SOLUBILITY

In Vitro

DMSO: 125 mg/mL (849.82 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	6.7986 mL	33.9928 mL	67.9856 mL
	5 mM	1.3597 mL	6.7986 mL	13.5971 mL
	10 mM	0.6799 mL	3.3993 mL	6.7986 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (14.14 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (14.14 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (14.14 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	Methylnitronitrosoguanidine (MNNG) is an orally active alkylating agent with toxic and mutagenic effects. Methylnitronitrosoguanidine can as a carcinogen and mutagen ^{[1][2]} . 50% water content, specifications are based on dry weight.
In Vitro	Methylnitronitrosoguanidine (MNNG, 0-1100 nM; 24 h) has toxic and mutagenic effects among 3 human diploid lymphoblast lines, MIT-2, WI-L2, and GM 130 ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

^{*} The compound is unstable in solutions, freshly prepared is recommended.

In Vivo

Methylnitronitrosoguanidine (MNNG; 200 mg/kg; p.o.) stimulates Wistar albino rats and increases the number of gastric cancer rats^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar albino rats ^[2]	
Dosage:	200 mg/kg	
Administration:	Oral administration, at 0 and 14th days	
Result:	Had the incidence of gastric cancer in Wistar albino rats is 100%.	

CUSTOMER VALIDATION

- Transl Res. 2023 Oct 30:S1931-5244(23)00179-2.
- J Ethnopharmacol. 31 October 2022, 115885.
- Dig Liver Dis. 2023 Dec 26:S1590-8658(23)01082-4.
- Toxicol Lett. 2024 Jan 4:S0378-4274(24)00002-X.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Slapikoff SA, et, al. Comparison of toxicity and mutagenicity of methylnitrosourea, methylnitrosoguanidine and ICR-191 among human lymphoblast lines. Mutat Res. 1980 May;70(3):365-71.

[2]. Zhang L, Jia B, et, al. Corilagin induces apoptosis and inhibits HMBG1/PI3K/AKT signaling pathways in a rat model of gastric carcinogenesis induced by methylnitronitrosoguanidine. Environ Toxicol. 2022 May;37(5):1222-1230.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA